learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 801 resultslearn phosphorus
learn Phospholipids
learn Epidermal Growth Factor
learn oligopeptide-71
Research
5 / 1000+ results
research Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG)
Green tea component EGCG could potentially promote human hair growth.
research A role of placental growth factor in hair growth
Placental growth factor may help treat hair loss.
research ANXA1 affects murine hair follicle growth through EGF signaling pathway
ANXA1 influences hair growth in mice through the EGF signaling pathway.
research 873 The effect of Cilostazol on hair growth: A novel therapeutic option for the treatment of hair loss
Cilostazol may help hair grow and could be a new treatment for hair loss.
research Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
Kaempferol promotes hair growth and could be a natural treatment for hair loss.
Community Join
5 / 1000+ resultscommunity Adipocyte lipolysis activates epithelial stem cells for hair regeneration through fatty acid metabolic signaling
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.